Next Article in Journal
Effects of Hydrosalpinx on Endometrial Receptivity and Uterine Microbiome: An Interesting Case of Double Uterus with Unilateral Hydrosalpinx
Next Article in Special Issue
Dysmetabolic Iron Overload Syndrome: Going beyond the Traditional Risk Factors Associated with Metabolic Syndrome
Previous Article in Journal
Diabetic Ketoacidosis Management: Updates and Challenges for Specific Patient Population
Previous Article in Special Issue
The Initial ATA Risk Classification, but Not the AJCC/TNM Stage, Predicts the Persistence or Relapse of Differentiated Thyroid Cancer in Long-Term Surveillance
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Endocrines
Volume 3
Issue 4
10.3390/endocrines3040067
endocrines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Growth Hormone-Releasing Hormone Antagonist JV-1-36 Suppresses Reactive Oxygen Species Generation in A549 Lung Cancer Cells

by
Khadeja-Tul Kubra
,
Mohammad S. Akhter
,
Kaitlyn Apperley
and
Nektarios Barabutis
*
School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana Monroe, 1800 Bienville Drive, Monroe, LA 71201, USA
*
Author to whom correspondence should be addressed.
Endocrines 2022, 3(4), 813-820; https://doi.org/10.3390/endocrines3040067
Submission received: 20 October 2022 / Revised: 24 November 2022 / Accepted: 7 December 2022 / Published: 9 December 2022
(This article belongs to the Special Issue Feature Papers in Endocrines)
Browse Figures
Versions Notes

Abstract

Growth hormone-releasing hormone (GHRH) and its receptors are expressed in a variety of human cancers, and have been involved in malignancies. GHRH antagonists (GHRHAnt) were developed to suppress tumor progression and metastasis. Previous studies demonstrate the involvement of reactive oxygen species (ROS) in cancer progression. Herein, we investigate the effect of a commercially available GHRH antagonist, namely JV-1-36, in the redox status of the A549 human cancer cell line. Our results suggest that this peptide significantly reduces ROS production in those cells in a time-dependent manner and counteracts H2O2-induced ROS. Our study supports the anti-oxidative effects of JV-1-36 and contributes in our knowledge towards the in vitro effects of GHRHAnt in cancers.
Keywords: inflammation; lung injury; endothelium; oxidative stress inflammation; lung injury; endothelium; oxidative stress

Share and Cite

MDPI and ACS Style

Kubra, K.-T.; Akhter, M.S.; Apperley, K.; Barabutis, N. Growth Hormone-Releasing Hormone Antagonist JV-1-36 Suppresses Reactive Oxygen Species Generation in A549 Lung Cancer Cells. Endocrines 2022, 3, 813-820. https://doi.org/10.3390/endocrines3040067

AMA Style

Kubra K-T, Akhter MS, Apperley K, Barabutis N. Growth Hormone-Releasing Hormone Antagonist JV-1-36 Suppresses Reactive Oxygen Species Generation in A549 Lung Cancer Cells. Endocrines. 2022; 3(4):813-820. https://doi.org/10.3390/endocrines3040067

Chicago/Turabian Style

Kubra, Khadeja-Tul, Mohammad S. Akhter, Kaitlyn Apperley, and Nektarios Barabutis. 2022. "Growth Hormone-Releasing Hormone Antagonist JV-1-36 Suppresses Reactive Oxygen Species Generation in A549 Lung Cancer Cells" Endocrines 3, no. 4: 813-820. https://doi.org/10.3390/endocrines3040067

APA Style

Kubra, K.-T., Akhter, M. S., Apperley, K., & Barabutis, N. (2022). Growth Hormone-Releasing Hormone Antagonist JV-1-36 Suppresses Reactive Oxygen Species Generation in A549 Lung Cancer Cells. Endocrines, 3(4), 813-820. https://doi.org/10.3390/endocrines3040067

Article Metrics

Back to TopTop